Long Term Prophylactic Therapy of Congenital Long QT Syndrome Type III (LQT3) With Ranolazine

Status

UNKNOWN

Phases

Phase 2

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT01728025

Enrollment

Registered

2012-11-16

Start date

2012-10-31

Completion date

2017-11-30

Last updated

2015-03-26

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Long QT Syndrome Type 3

Keywords

Long QT syndrome, Ranolazine

Brief summary

The purpose of this study is to determine whether ranolazine will reduce the risk of arrhythmic events in patients with long QT syndrome type 3.

Interventions

DRUGRanolazine

Study design

Allocation

Intervention model

SINGLE_GROUP

Primary purpose

PREVENTION

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

18 Years to 80 Years

Healthy volunteers

Inclusion criteria

* Long QT patients with genetic confirmation of carrier-status for the D1790G mutation in the SCN5A gene * Corrected QT interval \> 460 msec

Exclusion criteria

* Need for therapy with medications that are potent or moderately potent CYP3A inhibitors (such as ketoconazole, diltiazem, verapamil, macrolide antibiotics or HIV protease inhibitors)

Design outcomes

Primary

Measure	Time frame
Number of participants with syncope and/or documented ventricular arrhythmia	5 years

Secondary

Measure	Time frame
Change in corrected QT interval	within 30 days of initiation of Ranolazine treatment

Countries

Israel

Contacts

Primary ContactSami Viskin, MD

samiviskin@gmail.com972-3-6973311

Backup ContactJesaia Benhorin, MD

972-3-6973311

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 1, 2026